Clinical trials: Gastro Esophageal Junctional Cancer
Gastric Cancer, Esophageal Cancer
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
This is a phase I trial of CA-4948 in combination with FOLFOX/PD-1 inhibitor with or without trastuzumab for unresectable gastric, GEJ, and esophageal cancer.
- Conditions
- Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer
- Trial name
- NCT05187182
- Testing
- CA-4948, Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Lymphoma, Advanced Solid Tumors
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT04144140
- Testing
- E7766
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Gastric Adenocarcinoma
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e.
- Trial name
- FIDES-03 (NCT04604132)
- Testing
- Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
- Where
- 81 sites in United States, Argentina and 13 more
- Volunteers
- 47 people
- Sponsor
- Basilea Pharmaceutica
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
The purpose of the study is to assess the efficacy and safety and PK of AZD8931 plus paclitaxel versus paclitaxel alone in patients with metastatic, gastric or gastro-oesophageal junction, cancer.
- Trial name
- NCT01579578
- Testing
- AZD8931, Paclitaxel
- Where
- 15 sites in Germany, Japan and 3 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b
Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b
Gastric and gastro-oesophageal junction (GEJ) adenocarcinomas rank as the fifth leading cause of cancer globally. The standard treatment for resectable non-metastatic cT2-T4NX gastric or GEJ adenocarcinoma is perioperative FLOT…
- Trial name
- BEMAFLOT (NCT06967987)
- Testing
- Bemarituzumab + Flot regimen
- Where
- 12 sites in France
- Sponsor
- Institut Cancerologie de l'Ouest
Gastric Cancer, Gastro-oesophageal Junction Cancer
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or…
- Trial name
- NCT03957564
- Testing
- Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Qinghai University
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ)…
- Conditions
- Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
- Trial name
- ZODIAC (NCT06250036)
- Testing
- Single agent zimberelimab, Combination zimberelimab + domvanalimab
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Cancer
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal…
- Trial name
- NCT01220934
- Where
- Germany
- Volunteers
- 443 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer.
- Trial name
- NCT01130337
- Testing
- Capecitabine [Xeloda], Oxaliplatin, Trastuzumab [Herceptin]
- Where
- 30 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it.
- Trial name
- NCT04850729
- Testing
- non-intervention
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma
Gastric or gastroesophageal junction adenocarcinoma is commonly treated with chemotherapy before and after surgery. The chemotherapy regimen used in our institution, called DCF (docetaxel,cisplatic, 5-fluorouracil) is active…
- Trial name
- NCT01932580
- Testing
- FLOT (5-fluorouracil, oxaliplatin, docetaxel)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Epiphora Due to Insufficient Drainage, Left Side, Epiphora Due to Insufficient Drainage, Right Side
Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis
On the basis of minimally invasive Ivor Lewis operation for the treatment of lower thoracic esophageal cancer or esophageal gastric junction cancer, the purpose of this study is to compare the probability of anastomotic leakage…
- Trial name
- NCT05812495
- Testing
- Esophagogastric Side to Side Anastomosis, Esophagogastric End to Side Anastomosis
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stent Migration, GastroEsophageal Cancer
Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)
The aim of this prospective, controlled, randomized, multicentre, single-blind study is to compare the rate of intragastric migration of 2 types of esophageal stents with and without an anti-migration device placed for locally…
- Trial name
- ANTIMIG (NCT05431738)
- Testing
- Gastroesophageal stent placement
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Société Française d'Endoscopie Digestive
Gastro-Oesophageal Cancer
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
A randomised phase III, double-blind, placebo-controlled trial with 2:1 (regorafenib : placebo)
- Trial name
- INTEGRATEIIa (NCT02773524)
- Testing
- Regorafenib
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 250 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Colorectal Cancer, Gastric Cancer
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or…
- Conditions
- Colorectal Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- NCT04508140
- Testing
- Hepatic Biopsy, BO-112 with pembrolizumab
- Where
- 12 sites in Belgium, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Highlight Therapeutics
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.
- Conditions
- Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
- Trial name
- PLATFORM (NCT02678182)
- Testing
- Capecitabine, MEDI4736 (Durvalumab), Trastuzumab
- Where
- United Kingdom
- Volunteers
- 494 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Gastro-esophageal Cancer
PeRioperative Study of Exercise Training in Patients With Operable Cancer of the Gastroesophageal Junction
Background: For patients diagnosed with operable cancer of the gastro-esophageal junction (GEJ), the perioperative course of therapy is associated with severe deconditioning which includes weight loss and poor physical function…
- Trial name
- PRESET (NCT02722785)
- Testing
- Aerobic and Resistance Exercise Training
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Jesper Frank Christensen, PhD